Respiratory Infections
Conditions
Keywords
Respiratory infection, Viral infection, Food supplement, Goldtrain Plus (GT+)
Brief summary
General:Prospective, randomized, double blind controlled trial of the food supplement GOLDTRAIN PLUS, to assess its safety and efficacy in comparison to placebo in subjects with upper respiratory infection. Hypothesis: The food supplement GOLDTRAIN PLUS will be superior to placebo in shortening the time to recovery from the disease symptoms. Study design and outcome measures:Study population of 182 generally healthy subjects with acute respiratory infection randomized in 1:1 ratio to active supplement versus placebo treatment, with randomization stratified by site. The study supplement administration will be continued for 7 days, and patient global assessment (PGA) will be the main primary measurement tool, based on a self-reporting questionnaire filled and monitored every 12 hours for 7 consecutive days. Throat and nasal swabs determining type of viral infection, will be taken at inclusion of patient and a number of blood tests at the end of treatment to look for any adverse effects of the medication. Analysis and conclusion: All data-from the filled questionnaires, clinical follow up and laboratory studies will be analyzed by multivariate analysis to determine the efficacy of the supplement and its correlation to the clinical and laboratory parameters.
Interventions
DIETARY_SUPPLEMENTGardemont Goldtrain Plus (GT+)
Four tablets of 760 mg of GT+ administered three times a day for seven consecutive days and similar placebo tablets given to the control arm
Sponsors
Ben-Gurion University of the Negev
Clalit Health Services
Meir Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Signed Informed Consent 2. Age eligible (18 ≤ Age ≤ 90) 3. Respiratory infection with or without fever-
Exclusion criteria
1. Evidence of the bacterial infection 2. Symptoms suggestive of other than respiratory system illness (i.e. diarrhea, abdominal pain, skin rash, urinary symptoms). 3. Hospitalisation is planned 4. Surgery within previous 2 months 5. Pregnancy (women at childbirth age should have a urine beta-HCG test performed) 6. Subject with known renal dysfunction (creatinine ≥ 2 mg/dL) 7. Subject has history of debilitating liver dysfunction with elevation of liver enzymes and bilirubin levels to ≥ ULN 8. Participation in the active follow-up phase of another clinical study of an investigational drug or device 9. Known hypercalcemia -
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patient Global Assessment (PGA) | Seven days | Patient global assessment (PGA) will be a primary measurement, based on the self-reporting answer to the following question: What is your overall feeling as compared to the first day of treatment: worse, same or better. Time from the enrollment to the first 12 hours when the subject reports on a sustained improvement in symptoms (two consequent 12 hours periods) will be a primary outcome. The study supplement administration will be continued for 7 days. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of safety composite | 30 days | Death, hospitalizations, serious adverse effects |
Countries
Israel
Contacts
Primary ContactAssi Cicurel, MD
Backup ContactYael Peleg, MA
Outcome results
None listed